Corient Private Wealth LP Purchases Shares of 142,986 BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Corient Private Wealth LP acquired 142,986 BioCryst Pharmaceuticals shares worth approximately $1.43 million, giving it a 0.06% stake. Institutional investors collectively own 85.88% of the company.
• BioCryst reported quarterly revenue of $218.25 million, up 33.6% year over year and above estimates, while adjusted EPS of $0.30 exceeded the $0.15 consensus forecast.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $20.60 versus the stock’s recent price of $10.09.

Corient Private Wealth LP purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 142,986 shares of the biotechnology company's stock, valued at approximately $1,430,000. Corient Private Wealth LP owned 0.06% of BioCryst Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in BCRX. Larson Financial Group LLC lifted its stake in shares of BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 3,267 shares during the period. Allworth Financial LP acquired a new stake in BioCryst Pharmaceuticals during the 2nd quarter valued at approximately $52,000. Focus Partners Wealth acquired a new stake in BioCryst Pharmaceuticals during the 3rd quarter valued at approximately $77,000. Envestnet Portfolio Solutions Inc. bought a new position in BioCryst Pharmaceuticals during the 4th quarter worth approximately $81,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in BioCryst Pharmaceuticals during the 3rd quarter worth approximately $81,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $10.09 on Friday. The business's 50 day moving average price is $9.75 and its two-hundred day moving average price is $9.16. The firm has a market cap of $2.58 billion, a PE ratio of -6.73 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a 52-week low of $6.00 and a 52-week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The business had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. During the same period in the prior year, the firm earned $0.15 earnings per share. BioCryst Pharmaceuticals's revenue was up 33.6% on a year-over-year basis. Research analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Citizens Jmp boosted their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a "market outperform" rating in a research report on Thursday, May 7th. Cantor Fitzgerald lifted their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an "overweight" rating in a research note on Tuesday, June 30th. Royal Bank Of Canada lowered their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 29th. Finally, Wedbush cut their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, BioCryst Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $20.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.